First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis

First-line treatment options for PD-L1-negative lung adenocarcinoma: a real-world analysis

ObjectiveTo evaluate the optimal first-line treatment options for programmed death-ligand 1 (PD-L1) negative lung adenocarcinoma (LUAD) patients without common gene-alterations.MethodsA total of 159 PD-L1-negative LUAD patients without common gene-alterations were included. Chemotherapy was administ...

Full description

Saved in:
Bibliographic Details
Main Authors: Lijuan Chen, Jie Liu, Junfeng Lu, Xiufeng Hu, Erjing An, Yanqiu Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Oncology
Subjects:
lung adenocarcinoma
PD-L1 negative
first-line treatment
bevacizumab
immunotherapy
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1533048/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1533048/full

Similar Items